Regenerex Pharma (RGPX) 10-Q 7 Aug 24 2024 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Jun. 30, 2024	Aug. 07, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2024
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--03-31
Entity File Number	000-53230
Entity Registrant Name	REGENEREX PHARMA, INC.
Entity Central Index Key	0001357878
Entity Tax Identification Number	98-0479983
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	5348 Vegas Drive #177
Entity Address, City or Town	Las Vegas
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89108
City Area Code	(877)
Local Phone Number	761-7479
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		278,255,910

BALANCE SHEETS (UNAUDITED)

BALANCE SHEETS (UNAUDITED) - USD ($)	Jun. 30, 2024	Mar. 31, 2024
Current Assets
Cash and equivalents		$ 372
Prepaid expenses	2,357	2,540
Total Current Assets	2,357	2,912
Website, net of accumulated amortization of $29,986 and $29,272, as of June 30, 2024 and March 31, 2024, respectively	614	1,328
Furniture and computer equipment, net of accumulated depreciation of $2,030 and $1,600 as of June 30, 2024 and March 31, 2024	5,667	6,097
Right of use assets	720,452	756,343
Total Assets	729,090	766,680
Current Liabilities
Accounts payable	160,696	116,760
Related party advances	5,290	3,690
Accrued compensation	608,732	511,847
Other accrued liabilities	106,971	97,251
Current portion of notes payable	2,584,232	2,400,000
Current portion of lease liabilities	174,259	128,264
Total Current Liabilities	4,413,515	3,843,362
Notes payable, net of current portion		184,232
Lease liabilities, net of current portion	628,964	681,798
Total Liabilities	5,042,479	4,828,506
Commitments and Contingencies (Note 7)
Stockholders’ Deficit
Common stock: $0.001 par value: 675,000,000 shares authorized: 278,255,910, and 278,225,910 issued and outstanding at June 30, 2024 and March 31, 2024	278,256	278,226
Additional paid-in capital	1,296,765	1,275,798
Accumulated deficit	(5,888,410)	(5,615,850)
Total Stockholders’ Deficit	(4,313,389)	(4,061,826)
Total Liabilities and Stockholders’ Deficit	729,090	766,680
Shareholder [Member]
Current Liabilities
Current portion of notes payable	604,609	475,050
Notes payable, net of current portion		119,114
Other Affiliates [Member]
Current Liabilities
Current portion of notes payable	$ 168,726	$ 110,500

BALANCE SHEETS (UNAUDITED) (Par

BALANCE SHEETS (UNAUDITED) (Parenthetical) - USD ($)	Jun. 30, 2024	Mar. 31, 2024
Statement of Financial Position [Abstract]
Finite-Lived Intangible Assets, Accumulated Amortization	$ 29,986	$ 29,272
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	$ 2,030	$ 1,600
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	675,000,000	675,000,000
Common Stock, Shares, Issued	278,255,910	278,225,910
Common Stock, Shares, Outstanding	278,255,910	278,225,910

STATEMENTS OF OPERATIONS (UNAUD

STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Operating Expenses:
General and administrative	$ 254,280	$ 160,174
Total Operating Expenses	254,280	160,174
Operating Loss	(254,280)	(160,174)
Other (Expense):
Interest expense	(22,333)	(18,506)
Foreign currency gain (loss)	4,053	(6,895)
Total Other Expense	(18,280)	(25,401)
Net Loss	$ (272,560)	$ (185,575)
Basic and Diluted Loss per Common Share	$ 0	$ 0
Weighted Average Number of Common Shares Outstanding	278,226,240	277,156,286

STATEMENTS OF CASH FLOWS (UNAUD

STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	3 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash Flows from Operating Activities:
Net loss	$ (272,560)	$ (185,575)
Adjustments to reconcile net loss to cash flows used in operating activities:
Depreciation and amortization	1,144	831
Foreign currency adjustment	(4,053)	6,895
Stock-based compensation	20,997	34,554
Amortization of ROU assets, net of liabilities	29,052	380
Changes in operating assets and liabilities:
Prepaid expenses	183	(23,300)
Accounts payable	63,300	93,792
Accrued compensation	96,885
Other accrued liabilities	9,720	(48,814)
Net cash used in operating activities	(55,332)	(121,237)
Cash Flows from Investing Activities:
Purchase of furniture and computer equipment		(3,629)
Net cash used in investing activities		(3,629)
Cash Flows from Financing Activities:
Related party advances, net	1,600	1,485
Proceeds from sale of common stock and warrants		190,000
Net cash provided by financing activities	54,960	191,485
Increase (decrease) in cash and equivalents	(372)	66,619
Cash and cash equivalents, beginning of period	372	1,135
Cash and cash equivalents, end of period		67,754
Supplemental Cash Flow Information – Cash Paid For:
Income taxes
Interest
Non-Cash Investing and Financing Activities:
Accrued interest converted into note payable to shareholder	14,264	20,451
Accrued interest converted into note payable to related parties	4,866
Accrued interest converted into note payable		52,545
Operating leases, ROU asset and liabilities		953,535
Affiliated Entity [Member]
Cash Flows from Financing Activities:
Proceeds from notes payable to related party	$ 53,360

STATEMENTS OF STOCKHOLDERS' DEF

STATEMENTS OF STOCKHOLDERS' DEFICIT (UNAUDITED) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Mar. 31, 2023	$ 277,113	$ 671,963	$ (2,072,023)	$ (1,122,947)
Common Stock, Shares, Outstanding, Beginning Balance at Mar. 31, 2023	277,112,660
Shares and warrants sold for cash	190	189,810		190,000
Stock-based compensation	$ 30	$ 34,524		$ 34,554
Net loss			(185,575)	(185,575)
Ending balance, value at Jun. 30, 2023	$ 277,333	896,297	(2,257,598)	(1,083,968)
Common Stock, Shares, Outstanding, Ending Balance at Jun. 30, 2023	277,332,660
Beginning balance, value at Mar. 31, 2024	$ 278,226	1,275,798	(5,615,850)	$ (4,061,826)
Common Stock, Shares, Outstanding, Beginning Balance at Mar. 31, 2024	278,225,910			278,225,910
Stock-based compensation	$ 30	20,967		$ 20,997
Net loss			(272,560)	(272,560)
Ending balance, value at Jun. 30, 2024	$ 278,256	$ 1,296,765	$ (5,888,410)	$ (4,313,389)
Common Stock, Shares, Outstanding, Ending Balance at Jun. 30, 2024	278,255,910			278,255,910

NATURE OF OPERATIONS

NATURE OF OPERATIONS	3 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF OPERATIONS	NOTE 1 – NATURE OF OPERATIONS Regenerex Pharma, Inc., (the “Company” or “Regenerex”), was incorporated in the State of Nevada, United States of America, on November 18, 2005. On November 15, 2021, the Company entered into an Asset Purchase Agreement in which the Company purchased certain intellectual property in exchange for 150,000,000 shares of the Company’s common stock and up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15 th The Company received all rights and title to proprietary wound healing technologies platforms and formulas involving the application of wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns and surgical wounds. These unique products strategically position the Company to enter the wound treatment market in the U.S. Risks and Uncertainties Our business and our forward-looking statements involve substantial known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding the impacts of COVID-19, or other future pandemics on our business, results of operations, financial position, and cash flows. The Company has a lack of revenue history and has had a limited history of operations. No revenue has historically been derived from the assets purchased. Regenerex can give no assurance of success or profitability to the Company’s investors. The wound care healing space is well suited for Home Care service providers that are funded by the US Government. Strategic planning and development will be performed internally by the Company.

BASIS OF PRESENTATION OF INTERI

BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS	3 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS	NOTE 2 – BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States of America. The accompanying interim unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. In our opinion, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three months ended June 30, 2024 are not necessarily indicative of the results that may be expected for the year ending March 31, 2025. Notes to the unaudited interim financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the year ended March 31, 2024 have been omitted. This report should be read in conjunction with the audited financial statements and the footnotes thereto for the fiscal year ended March 31, 2024 included within the Company’s Annual Report on Form 10-K as filed with the Securities and Exchange Commission.

GOING CONCERN

GOING CONCERN	3 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 3 – GOING CONCERN These financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which contemplate the continuation of the Company as a going concern. The Company has incurred losses from operations and had an accumulated deficit of $5,888,410 as of June 30, 2024. The Company also has excess liabilities over assets of $4,313,389. These factors raise doubt about the Company’s ability to continue as a going concern. The Company requires significant cash to launch its business and reduce its payable. Management’s plans are to actively seek capital to enable the Company to add new products and/or services to ultimately achieve profitability. However, management cannot provide assurance that they can raise sufficient capital and whether the Company will ultimately achieve profitability, become cash flow positive, or raise additional debt and/or equity capital. If the Company is unable to raise additional capital in the near future or meet financing requirements, management expects that the Company will need to curtail operations, seek additional capital on less favorable terms, and/or pursue other remedial measures. These financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company become unable to continue as a going concern.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 4 –SIGNIFICANT ACCOUNTING POLICIES Revenue Recognition The Company will record revenue under Accounting Standards Codification (“ASC”) 606 by 1) identifying the contract with the customer 2) identifying the performance obligations in the contract 3) determining the transaction price, 4) allocating the transaction price to the required performance obligations in the contract, and 5) recognizing revenue when or as the companies satisfies a performance obligation. We expect to generate revenue from home care service providers that are funded by the U.S. Government, State Medicaid Programs, International Health Care Programs, Veteran’s administration, Prison system, Home Health Care Providers, and other applicable Medicare reimbursement models. The Company will defer revenue where the earnings process is not yet complete. To date, no revenue has been generated from the asset acquisition disclosed in Note 1. Earnings per Share Earnings per share is reported in accordance with FASB Topic 260 “ Earnings per Share During the three months ended June 30, 2024, the Company excluded the outstanding stock warrants from its calculation of earnings per share, as the warrants would be anti-dilutive. Conversion of outstanding warrants may result in approximately one million additional shares of common stock outstanding. As of June 30, 2024 and 2023, the Company had common share warrants outstanding of 2,734,250 and 1,115,000, respectively. Website Expenditures related to the planning and operation of the Company’s website are expensed as incurred. Expenditures related to the website application and infrastructure development are capitalized and amortized over the website’s estimated useful life of three (3) years. Amortization expense for the three months ended June 30, 2024 and 2023 was $714 and $715, respectively. Furniture and Computer Equipment Furniture and computer equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of three (3) to five (5) years. Depreciation expense for the three months ended June 30, 2024 and 2023 was $430 and $116. Significant betterments are capitalized while purchases under $500 are expensed as incurred. Right of Use Assets and Lease Liabilities The Company has active operating lease arrangements for office space, production equipment, and production facilities. The Company is required to make fixed minimum rent payments relating to its right to use the underlying leased asset. In accordance with the adoption of ASC 842, the Company recorded right-of-use assets and related lease liabilities for these leases as of June 2024. The Company’s lease agreements do not provide an implicit borrowing rate. Therefore, the Company used a benchmark approach to derive an incremental borrowing rate of 10% to discount each of its lease liabilities based on the remaining lease term. Stock-Based Payments The Company recognizes the cost of share-based payment awards on a straight-line attribution basis over the requisite employee service period and over the non-employee’s period of providing goods or services, net of estimated forfeitures. Determining the fair value of share-based awards at the measurement date requires judgment, including estimating the expected term that stock options will be outstanding prior to exercise and the associated volatility. The Company estimates the fair value of options granted using the Black-Scholes valuation model. The expected life of the options used in this calculation is the period of time the options are expected to be outstanding. Expected stock price volatility is based on the historical volatility of comparable public companies’ common stock for a period approximating the expected life, and the risk-free interest rate is based on the implied yield available on US Treasury zero-coupon issues approximating the expected life. Judgment is also required in estimating the number of share-based awards that will be forfeited prior to vesting. The fair value of restricted stock awards is based on the fair value of the Company’s common stock on the date of the grant. Research and Development We incur research and development costs during the process of researching and developing additional technologies purchased and future manufacturing processes. Our research and development costs consist primarily of the purchase of additional intellectual property that we will use in the development of our planned product. We expense these costs as incurred until the resulting product has been completed, tested, and made ready for commercial use. Recent Accounting Pronouncements The Financial Accounting Standards Board issued Accounting Standards Updates (“ASU”) to amend the authoritative literature in the Accounting Standards Codification (“ASC”). There have been a number of ASUs to date that amend the original text of the ASC. The Company believes those updates issued-to-date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company, or (iv) are not expected to have a significant impact on the Company.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	3 Months Ended
	Jun. 30, 2024
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 5 – RELATED PARTY TRANSACTIONS The Company purchased assets from the Company’s current Chief Executive Officer (“CEO”) and Secretary/Treasurer (see note 6). On June 10, 2023, the Company, has entered into an agreement with Woundcare Labs, LLC., a party related to the CFO and CEO of the Company, to lease a plant and to lease equipment in Tennessee. (see note 8). Related Party Advances The Company’s former Chief Financial Officer (“CFO”) had advanced the Company monies for operating expenses; no amounts were advanced during the periods presented. The advances were due on demand, but no later than June 30, 2023. The related party advances began to accrue interest at ten (10) percent per annum on July 1, 2019. During the three months ended June 30, 2023, this note was transferred to a relative of the former CFO and was renewed upon maturity in the principal amount of $131,687 plus interest accrued as at June 30, 2023 in the amount of $52,545. Interest expense was $3,285 and $3,285 during the three-month periods ended June 30, 2024 and 2023, respectively. This transaction is no longer considered related party in nature, and thus is included in Notes payable in the accompanying balance sheet. The Company’s Chief Executive Officer (“CFO”) advanced the Company monies for operating expenses in the net amount of $1,600 and $1,485 during the three months ended June 30, 2024 and June 30, 2023. The advances are due on demand. The related party advances totaled $5,290 and $3,690 as at June 30, 2024 and March 31, 2024, respectively. Notes Payable to Related Parties During the three-month periods ended June 30, 2024 and 2023, the Company’s CFO and the Company’s CEO advanced the Company monies for operating expenses in the amount of $53,360 and $0, respectively. No repayment was made during the three-month periods ended June 30, 2024 and 2023. The advances are due on demand and accrue interest at ten (10) percent per annum. Repayment is due no later than six months after the date of issue and range from September 4, 2024 to December 21, 2024. The related party notes payable totaled $168,726 and $110,500 as at June 30, 2024 and March 31, 2024. Interest expenses were $3,169 and $981 during the three-month periods ended June 30, 2024 and 2023, respectively, which is included in other accrued liabilities. Note Payable to Shareholder As at June 30, 2024 and March 31, 2024, the Company had various promissory notes with total outstanding principal balances of $604,609 and $594,164, respectively, due to a shareholder of the Company. These notes are unsecured, bear interest at 10% per annum, and have maturity dates ranging from July 2, 2024 to June 17, 2025. During the three-months ended June 30, 2024, notes with principal amounts totaling approximately $38,500 ($51,600 Canadian Funds) that came due during the period were reissued in the total principal amount of approximately $41,800 ($55,980 Canadian Funds) which included the principal amount plus accrued interest of approximately $3,300 ($4,380 Canadian Funds.) These notes are unsecured and bear interest at ten (10) percent per annum with principal and interest due six (6) months after the date of issue. During the three-months ended June 30, 2024, notes with principal amounts totaling approximately $116,735 that came due during the period were reissued in the total principal amount of $127,672 which included the principal amount plus accrued interest of $10,937. These notes are unsecured and bear interest at ten (10) percent per annum with principal and interest due six (6) months after the date of issue. Aggregate interest expense was $14,570 and $14,240 during the three months ended June 30, 2024 and 2023, which is included in other accrued liabilities at June 30, 2024 and March 31, 2024, respectively.

INTANGIBLE ASSETS AND INTELLECT

INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY	3 Months Ended
	Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY	NOTE 6 – INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY On November 15, 2021, the Company entered into an Asset Purchase Agreement in which the Company purchased certain intellectual property in exchange for 150,000,000 shares of the Company’s common stock and up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15th of the following month, for a period of 60 months. The Company received all rights and title to proprietary wound healing technologies platforms and formulas involving the application of wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns and surgical wounds. These unique products strategically position the Company to enter and capture a high proportionate market share in the U.S. On August 17, 2023, the Company entered into an Agreement to Purchase Technology Platforms in which the Company purchased certain intellectual property in exchange for a two million four hundred thousand dollars ($2,400,000) note payable. The intellectual property that was purchased requires further development prior to the product being finalized and produced so it has been expensed as research and development. The note payable is due within twelve (12) months of the date of the agreement and is included in current liabilities. If the Company has not raised a minimum of ten million dollars ($10,000,000) in sales within twelve (12) months of the agreement date, or a minimum of ten million dollars ($10,000,000) in investment, the seller will extend the payment for a further period of twelve (12) months for a 10% payment of the outstanding balance. The Technology Platforms include but are not limited to: A. B. C. D. E. F. G. H. I. J. K. Products: 1. 2. 3.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 7 – COMMITMENTS AND CONTINGENCIES The Company is not currently involved with and does not have knowledge of any pending or threatened litigation against the Company or any of its officers. See Note 6 for discussion of the $10,000,000 in contingent consideration to be paid in connection with the November 15, 2021 Asset Purchase Agreement. Payments made to the Company’s CEO and CFO in connection with the Asset Purchase Agreement are $43,500 as at June 30, 2024 and March 31, 2024. The outstanding liability of $15,488 as at June 30, 2024 and March 31, 2024 is included in other accrued liabilities.

OPERATING LEASES

OPERATING LEASES	3 Months Ended
	Jun. 30, 2024
Operating Leases
OPERATING LEASES	NOTE 8 – OPERATING LEASES On April 1, 2023, the Company entered into an office lease agreement commencing in May 2023 which expires on April 30, 2028. Under this agreement, the monthly rental payments are $1,650 throughout the term of the lease. The Company is required to pay for all utilities used on the premises and has paid a security deposit of $800 which is included in prepaid expenses. On June 10, 2023, the Company entered into a plant facility lease agreement with a related party commencing June 9, 2023 which expires on June 30, 2028. Under this agreement, the monthly rental payments are $18,000 throughout the term of the lease excepting the month of June 2023 the rent is $7,920, The Company is working to have the premise certified by the FDA and will pay all related costs. Until the certification is complete, the monthly rent is reduced by forty (40%) percent to $10,800. Under this agreement, the Company is also leasing the equipment in the plant facility through five (5) annual rent payments of $10,000, which are due on the 15th day of each June from June 2023 to June 2027. The lease payment due June 15, 2024 is extended to September 15, 2024 with an extension fee of five hundred ($500) due August 5, 2024. During the three-month periods ended June 30, 2024 and 2023 the operating lease cost was $55,602 and $21,600 respectively and is included in general and administrative expenses in the accompanying financial statements.

STOCKHOLDERS_ DEFICIT

STOCKHOLDERS’ DEFICIT	3 Months Ended
	Jun. 30, 2024
Equity [Abstract]
STOCKHOLDERS’ DEFICIT	NOTE 9 – STOCKHOLDERS’ DEFICIT The Company has authorized the issuance of 675,000,000 shares of common stock with a par value of $0.001 per share. During each of the three months ended June 30, 2024 and 2023, the Company issued 30,000 shares to board members for services rendered. During each of the three months ended June 30, 2024 and 2023, stock-based compensation of $5,400 was expensed within general and administrative expenses. During the three months ended June 30, 2024 and 2023, the Company issued 126,000 and 45,000 warrants to board members and consultants for services rendered with a total grant date fair value of $12,561 and $4,554, respectively. Total stock-based compensation expense of $15,597 and $4,554, respectively, was recorded in connection with these awards during the three-month periods ended June 30, 2024 and 2023. The warrants are vested and contain an exercise price of $0.33 per share, and expire on dates ranging from July 1, 2029 to July 1, 2030. The warrant fair values were estimated using a Black Scholes model with a 5-year expected term, risk-free interest rate ranging from 4.33% to of 5.19%, a dividend yield of 0%, and an annualized standard deviation of stock price volatility of 80.0%. The risk-free interest rate assumptions for options granted is based upon observed interest rates on the United States government securities appropriate for the expected term of the equity awards. As of the date of this valuation, the Companies stock was not trading. The volatility was not calculated on each date shares were issued but was calculated at the end of the quarterly reporting period prior to the date the warrants were issued. The Company will continue to monitor peer companies and other relevant factors used to measure expected volatility for future equipment award grants, until such time that the Company’s Common Stock has enough market history to use historical volatility. The dividend yield assumption for equity awards granted is based on Company’s history and expectation of dividend payouts. The Company has never declared or paid any cash dividends on its Common Stock, and the Company does not anticipate paying any cash dividends in the foreseeable future. The closing stock price of the Company’s common stock is not available as the Company’s stock is not trading. As a result, the Board of Directors and management determined the fair value of the common stock to be $0.18 per share based upon an allocation of the recent cash price paid for common stock and warrants. As of June 30, 2024, 2,734,250 warrants had been issued all of which are vested. None of the warrants have been exercised.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Jun. 30, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 10 – SUBSEQUENT EVENTS Subsequent to June 30, 2024, one (1) promissory note with a shareholder was reissued in the principal amount of $1,081 which included the original principal of $901 plus interest of $180. Subsequent to June 30, 2024, six (6) promissory notes with a shareholder were reissued in the principal amount of approximately $101,000 ($139,410 Canadian Funds) which included the original principal of approximately $95,100 ($131,400 Canadian Funds) plus interest of approximately $5,900 ($8,010 Canadian Funds). These notes bear interest at ten (10) percent per annum with principal and interest due from six months after the date of issue ranging from January 2, 2025 to February 7, 2025. Subsequent to June 30, 2024, one (1) promissory note with a related party was issued in the amount of fifty-six thousand five hundred dollars ($56,500). The note is unsecured and bears interest at ten (10) percent per annum with principal and interest due January 18, 2025.

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Revenue Recognition	Revenue Recognition The Company will record revenue under Accounting Standards Codification (“ASC”) 606 by 1) identifying the contract with the customer 2) identifying the performance obligations in the contract 3) determining the transaction price, 4) allocating the transaction price to the required performance obligations in the contract, and 5) recognizing revenue when or as the companies satisfies a performance obligation. We expect to generate revenue from home care service providers that are funded by the U.S. Government, State Medicaid Programs, International Health Care Programs, Veteran’s administration, Prison system, Home Health Care Providers, and other applicable Medicare reimbursement models. The Company will defer revenue where the earnings process is not yet complete. To date, no revenue has been generated from the asset acquisition disclosed in Note 1.
Earnings per Share	Earnings per Share Earnings per share is reported in accordance with FASB Topic 260 “ Earnings per Share During the three months ended June 30, 2024, the Company excluded the outstanding stock warrants from its calculation of earnings per share, as the warrants would be anti-dilutive. Conversion of outstanding warrants may result in approximately one million additional shares of common stock outstanding. As of June 30, 2024 and 2023, the Company had common share warrants outstanding of 2,734,250 and 1,115,000, respectively.
Website	Website Expenditures related to the planning and operation of the Company’s website are expensed as incurred. Expenditures related to the website application and infrastructure development are capitalized and amortized over the website’s estimated useful life of three (3) years. Amortization expense for the three months ended June 30, 2024 and 2023 was $714 and $715, respectively.
Furniture and Computer Equipment	Furniture and Computer Equipment Furniture and computer equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of three (3) to five (5) years. Depreciation expense for the three months ended June 30, 2024 and 2023 was $430 and $116. Significant betterments are capitalized while purchases under $500 are expensed as incurred.
Right of Use Assets and Lease Liabilities	Right of Use Assets and Lease Liabilities The Company has active operating lease arrangements for office space, production equipment, and production facilities. The Company is required to make fixed minimum rent payments relating to its right to use the underlying leased asset. In accordance with the adoption of ASC 842, the Company recorded right-of-use assets and related lease liabilities for these leases as of June 2024. The Company’s lease agreements do not provide an implicit borrowing rate. Therefore, the Company used a benchmark approach to derive an incremental borrowing rate of 10% to discount each of its lease liabilities based on the remaining lease term.
Stock-Based Payments	Stock-Based Payments The Company recognizes the cost of share-based payment awards on a straight-line attribution basis over the requisite employee service period and over the non-employee’s period of providing goods or services, net of estimated forfeitures. Determining the fair value of share-based awards at the measurement date requires judgment, including estimating the expected term that stock options will be outstanding prior to exercise and the associated volatility. The Company estimates the fair value of options granted using the Black-Scholes valuation model. The expected life of the options used in this calculation is the period of time the options are expected to be outstanding. Expected stock price volatility is based on the historical volatility of comparable public companies’ common stock for a period approximating the expected life, and the risk-free interest rate is based on the implied yield available on US Treasury zero-coupon issues approximating the expected life. Judgment is also required in estimating the number of share-based awards that will be forfeited prior to vesting. The fair value of restricted stock awards is based on the fair value of the Company’s common stock on the date of the grant.
Research and Development	Research and Development We incur research and development costs during the process of researching and developing additional technologies purchased and future manufacturing processes. Our research and development costs consist primarily of the purchase of additional intellectual property that we will use in the development of our planned product. We expense these costs as incurred until the resulting product has been completed, tested, and made ready for commercial use.
Recent Accounting Pronouncements	Recent Accounting Pronouncements The Financial Accounting Standards Board issued Accounting Standards Updates (“ASU”) to amend the authoritative literature in the Accounting Standards Codification (“ASC”). There have been a number of ASUs to date that amend the original text of the ASC. The Company believes those updates issued-to-date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company, or (iv) are not expected to have a significant impact on the Company.

NATURE OF OPERATIONS (Details N

NATURE OF OPERATIONS (Details Narrative) - USD ($)	3 Months Ended
	Jun. 30, 2024	Nov. 15, 2021
Entity Incorporation, Date of Incorporation	Nov. 18, 2005
Asset Acquisition, Contingent Consideration, Liability		$ 10,000,000
Purchase Intellectual Property [Member]
Shares, Issued		150,000,000

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Equity, Attributable to Parent	$ 4,313,389	$ 4,061,826	$ 1,083,968	$ 1,122,947

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Property, Plant and Equipment [Line Items]
Class of Warrant or Right, Outstanding	2,734,250	1,115,000
Finite-Lived Intangible Asset, Useful Life	3 years
Amortization of Intangible Assets	$ 714	$ 715
Other Depreciation and Amortization	$ 430	$ 116
Lessee, Finance Lease, Discount Rate	10%
Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Mar. 31, 2024
Related Party Transaction [Line Items]
Related Party Transaction, Rate	10%
[custom:RelatedPartyAdvances-0]	$ 5,290		$ 3,690
Interest Expense, Operating and Nonoperating	22,333	$ 18,506
[custom:NotesPayableRelatedParties-0]	168,726
[custom:NotesPayableToRelatedPartiesNetOfCurrentPortion-0]			110,500
Interest Expense, Debt	3,169	981
Accrued Liabilities, Current	106,971		97,251
Aggregate Interest Expense [Member]
Related Party Transaction [Line Items]
Accrued Liabilities, Current	14,570	14,240
Reissued Notes [Member]
Related Party Transaction [Line Items]
Notes Payable	38,500
Long-Term Debt, Gross	41,800
Interest Payable, Current	3,300
Reissued Notes 2 [Member]
Related Party Transaction [Line Items]
Notes Payable	116,735
Long-Term Debt, Gross	127,672
Interest Payable, Current	10,937
Chief Financial Officer [Member]
Related Party Transaction [Line Items]
Notes and Loans Payable	131,687
[custom:RelatedPartyAdvances-0]	52,545
Affiliates [Member]
Related Party Transaction [Line Items]
Interest Expense, Operating and Nonoperating	3,285	3,285
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
[custom:RelatedPartyAdvances-0]	1,600	1,485
Chief Executive Officer And Chief Financial Officer [Member]
Related Party Transaction [Line Items]
Notes and Loans Payable	$ 53,360	$ 0
Debt Instrument, Interest Rate During Period	10%
Majority Shareholder [Member]
Related Party Transaction [Line Items]
Notes and Loans Payable	$ 604,609		$ 594,164

INTANGIBLE ASSETS AND INTELLE_2

INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY (Details Narrative)	1 Months Ended
	Nov. 15, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Business Combination, Contingent Consideration Arrangements, Description	up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15th of the following month, for a period of 60 months.

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	3 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Mar. 31, 2024	Nov. 15, 2021
Assets Sold under Agreements to Repurchase [Line Items]
Asset Acquisition, Contingent Consideration, Liability				$ 10,000,000
General and Administrative Expense	$ 254,280	$ 160,174
Accrued Liabilities, Current	106,971		$ 97,251
Asset Purchase Agreement Liability [Member]
Assets Sold under Agreements to Repurchase [Line Items]
Accrued Liabilities, Current	15,488
Chief Executive Officer And Chief Financial Officer [Member]
Assets Sold under Agreements to Repurchase [Line Items]
General and Administrative Expense	$ 43,500

OPERATING LEASES (Details Narra

OPERATING LEASES (Details Narrative) - USD ($)	3 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Mar. 31, 2024
Lessee, Lease, Description [Line Items]
Prepaid Expense, Current	$ 2,357		$ 2,540
Lessee, Operating Lease, Description	On June 10, 2023, the Company entered into a plant facility lease agreement with a related party commencing June 9, 2023 which expires on June 30, 2028. Under this agreement, the monthly rental payments are $18,000 throughout the term of the lease excepting the month of June 2023 the rent is $7,920, The Company is working to have the premise certified by the FDA and will pay all related costs. Until the certification is complete, the monthly rent is reduced by forty (40%) percent to $10,800. Under this agreement, the Company is also leasing the equipment in the plant facility through five (5) annual rent payments of $10,000, which are due on the 15th day of each June from June 2023 to June 2027. The lease payment due June 15, 2024 is extended to September 15, 2024 with an extension fee of five hundred ($500) due August 5, 2024.
Office Lease [Member] | Security Deposit [Member]
Lessee, Lease, Description [Line Items]
Prepaid Expense, Current	$ 800
Plant Facility [Member]
Lessee, Lease, Description [Line Items]
Capital Lease Obligations, Current	7,920
Plant Facility [Member] | Monthly Rental Payments [Member]
Lessee, Lease, Description [Line Items]
Operating Leases, Future Minimum Payments Due	18,000
Plant Lease [Member]
Lessee, Lease, Description [Line Items]
Operating Lease, Cost	$ 55,602	$ 21,600

STOCKHOLDERS_ DEFICIT (Details

STOCKHOLDERS’ DEFICIT (Details Narrative) - USD ($)	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023
Defined Benefit Plan Disclosure [Line Items]
Common Stock, Shares Authorized	675,000,000	675,000,000
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Class of Warrant or Right, Outstanding	2,734,250		1,115,000
Board Members And Consultants [Member] | Services Rendered [Member]
Defined Benefit Plan Disclosure [Line Items]
Class of Warrant or Right, Outstanding	126,000		45,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value	$ 12,561		$ 4,554
[custom:StockBasedCompensationUnrecognizedCompensationCost-0]	$ 15,597		$ 4,554
Board Members And Consultants [Member] | Services Rendered [Member] | Warrants [Member]
Defined Benefit Plan Disclosure [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price	$ 0.33

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - Subsequent Event [Member] - USD ($)	1 Months Ended
	Jul. 31, 2024	Jul. 01, 2024
Reissued Notes 1 [Member]
Subsequent Event [Line Items]
Debt Instrument, Repurchase Amount		$ 1,081
Debt Instrument, Face Amount		901
Debt Instrument, Increase, Accrued Interest	$ 180
Reissued Notes 2 [Member]
Subsequent Event [Line Items]
Debt Instrument, Repurchase Amount		101,000
Debt Instrument, Face Amount		$ 95,100
Debt Instrument, Increase, Accrued Interest	$ 5,900
Reissued Notes [Member]
Subsequent Event [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		10%
Debt Instrument, Maturity Date Range, Start	Jan. 02, 2025
Debt Instrument, Maturity Date Range, End	Feb. 07, 2025
Reissued Notes 3 [Member]
Subsequent Event [Line Items]
Debt Instrument, Repurchase Amount		$ 56,500
Debt Instrument, Interest Rate, Stated Percentage		10%
Debt Instrument, Maturity Date Range, Start	Jan. 18, 2025